Biotech Values

[DewDiligence]

Re: AMGN /Repatha CVOT

I previously posted (#msg-128464735) that I would be genuinely impressed if the primary endpoint showed a relative risk reduction of 30%, but the actual outcome on the primary endpoint (HR=0.85) did not come close.

The secondary endpoint (composite of CV death, MI, stroke) was only a little better at HR=0.80.

Most discouraging, however, was that CV-death as an individual endpoint had HR>1 (i.e. the Repatha arm was worse than the control arm), and the same was true for all-cause mortality.